Proceedings of the Third International Congress on Uremia Research. September 17-20, 2003. Taormina-Messina, Italy.
Semin Nephrol. 2004 Sep;24(5):395-536
Factors for increased morbidity and mortality in uremia: hyperphosphatemia.
Semin Nephrol. 2004 Sep;24(5):396-400
Mechanisms of vascular calcification in uremia.
Semin Nephrol. 2004 Sep;24(5):401-2
Arterial calcification in chronic kidney disease.
Semin Nephrol. 2004 Sep;24(5):403-7
C-reactive protein is a significant predictor of vascular calcification of both aorta and hand arteries.
Semin Nephrol. 2004 Sep;24(5):408-12
Uremic vasculopathy.
Semin Nephrol. 2004 Sep;24(5):413-6
Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients.
Semin Nephrol. 2004 Sep;24(5):417-22
Roles of metabolic and endocrinological alterations in atherosclerosis and cardiovascular disease in renal failure: another form of metabolic syndrome.
Semin Nephrol. 2004 Sep;24(5):423-5
Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action.
Semin Nephrol. 2004 Sep;24(5):426-30
Inflammation: cause of vascular disease and malnutrition in dialysis patients.
Semin Nephrol. 2004 Sep;24(5):431-6
New cellular and molecular approaches for the treatment of cardiac disease.
Semin Nephrol. 2004 Sep;24(5):437-40
Chronic systemic inflammation in uremia: potential therapeutic approaches.
Semin Nephrol. 2004 Sep;24(5):441-5
Management of calcium and bone abnormalities in hemodialysis patients.
Semin Nephrol. 2004 Sep;24(5):446-8
Sagliker syndrome: uglifying human face appearance in late and severe secondary hyperparathyroidism in chronic renal failure.
Semin Nephrol. 2004 Sep;24(5):449-55
Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism.
Semin Nephrol. 2004 Sep;24(5):456-9
Calcimimetic agents for the treatment of secondary hyperparathyroidism.
Semin Nephrol. 2004 Sep;24(5):460-3
Carnitine system in uremic patients: molecular and clinical aspects.
Semin Nephrol. 2004 Sep;24(5):464-8
Oxidative stress in uremia: nature, mechanisms, and potential consequences.
Semin Nephrol. 2004 Sep;24(5):469-73
Genomic damage in end-stage renal failure: potential involvement of advanced glycation end products and carbonyl stress.
Semin Nephrol. 2004 Sep;24(5):474-8
Disturbances of purine nucleotide metabolism in uremia.
Semin Nephrol. 2004 Sep;24(5):479-83
Cellular mechanisms causing loss of muscle mass in kidney disease.
Semin Nephrol. 2004 Sep;24(5):484-7
Ultrastructural changes of corpora cavernosa in men with erectile dysfunction and chronic renal failure.
Semin Nephrol. 2004 Sep;24(5):488-91
The role of interleukin-6 and of its soluble receptors in the biocompatibility of dialysis treatment.
Semin Nephrol. 2004 Sep;24(5):492-4
Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients.
Semin Nephrol. 2004 Sep;24(5):495-501
Advanced glycation end-products and peritoneal sclerosis.
Semin Nephrol. 2004 Sep;24(5):502-5
Continuum of therapy in progressive renal diseases (from predialysis to transplantation): analysis of a new organizational model.
Semin Nephrol. 2004 Sep;24(5):506-24
Vitamin E-coated dialyzer and antioxidant defense parameters: three-month study.
Semin Nephrol. 2004 Sep;24(5):525-31
Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry disease.
Semin Nephrol. 2004 Sep;24(5):532-6